Table 4 The clinical parameters of Low Risk and High Risk groups

Renal impairment

14

(13.5%)

33

(31.7%)

0.001^‡)

Age (years)

76

[33–95]

83

[19–98]

0.004^†)

Sex (M/F)

54/54

63/41

-

Height (cm)

160

[138–180]

160

[137–175]

0.988^†)

Weight (kg)

51.7

[29.2-124.6]

48.9

[27.0-135.7]

0.451^†)

Ccr (mL/min)

55.3

[14.0-120]

46.9

[4.9–120]

0.045^†)

BMI

20.2

[12.5–47.5]

20.0

[11.7–49.8]

0.478^†)

Dehydration^‖)

70

(64.8%)

81

(77.9%)

0.036^‡)

BUN (mg/dL)

18.7

[4.3–81.5]

22.3

[6.5–145.0]

0.004^†)

Cr (mg/dL)

0.72

[0.26–6.7]

0.74

[0.25–5.04]

0.505^†)

Initial Dose (mg/kg)

24.9

[9.0-46.7]

26.3

[7.5–55.6]

0.181^†)

Maintenance Dose (mg/kg/day)

28.8

[7.4–63.9]

23.7

[3.5–62.3]

0.004^†)

Peak blood concentration (µg/mL)

25.5

[12.1–56.8]

26.5

[8.5-120.4]

0.162^†)

Trough blood concentration (µg/mL)

15.6

[3.0-42.1]

16.4

[4.8–49.8]

0.060^†)

Initial Blood Sampling Measured AUC (mg·h/L)

492

[259–1291]

552

[237–1975]

0.095^†)

AUCss (mg·h/L)

572

[306–1217]

573

[230–1984]

0.500^†)

Cumulative AUC(mg·h/L) ^¶)

5754

[1117–26181]

6402

[1011–37078]

0.349^†)

Days of administration (days)

11.5

[3–47]

13.0

[3–47]

0.196^†)

Periods before the onset of nephrotoxicity (days)

11

[3–41]

11.5

[3–47]

0.689^†)

Dosing for more than 14 days

36

(33.3%)

47

(45.2%)

0.077^‡)